Overactive urinary bladder in elderly female patients: treatment specificities and drug interactions

Česká verzia

Authors: Lukáš Horčička ¹; Eva Topinková ²
Authors place of work: GONA, spol. s r. o., Praha ¹; Geriatrická klinika 1. LF UK a VFN v Praze ²
Published in the journal: Vnitř Lék 2018; 64(11): 1085-1090
Category:

Summary

Aging is an inevitable process in the life of each organism and it is no different in the human world. According to the world statistics and demographic data, an ever increasing group in our population live to a ripe old age. The paper deals with pharmacological therapy for overactive bladder (OAB) in older women while also considering frequent comorbidities in older age. The prevalence of OAB at this life stage is greater as compared to other, more serious diseases. There are less clinical studies on geriatric patients than those focusing on younger age categories. The effect of pharmacotherapy with antimuscarinics against placebo is demonstrable within all age groups including people aged over 75. With regard to polypharmacotherapy in older adults, antimuscarinics may intervene in drug interactions. Therefore the authors draw attention to these risk factors and the ways to prevent them.

Key words:

drug interactions – geriatry – overactive bladder – urinary incontinence

Zdroje

Chancellor MB, De Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics 2007; 62(5): 15–24.
Krhut J. Hyperaktivní močový měchýř. Maxdorf: Praha 2007. ISBN 978–80–7345–125–7.
Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive Bladder. Drug Saf 2011; 34(9): 733–754. Dostupné z DOI: <http://dx.doi.org/10.2165/11592790–000000000–00000>.
Mašata J. Anticholinergní látky v léčbě hyperaktivního močového měchýře. Remedia 2007; 17(1): 89–100.
Matoušková M. Solifenacin. Remedia 2009; 19(3): 170–175.
Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol Praxi 2010; 11(5): 241–246.
Topinková E. Nežádoucí účinky antimuskarinik na centrální nervový systém. Urol List 2012; 10(1): 69–74.
Topinková E. Jsou antimuskarinika v léčbě hyperaktivního močového měchýře stejně účinná a bezpečná i u seniorů? Medicína po promoci 2012; 13(Suppl 3): 21–28.
Madersbacher M, Awad S, Fall M et al. WHO Statements: Urge Inkontinenz beim älteren Menschen – supraspinale Reflexinkontinenz. Urologe B 1998; 38(Suppl 2): 10.
Kachlířová Z, Horčička L. Hyperaktivní močový měchýř – možnosti léčby v roce 2012. Remedia 2012; 22(5): 320–326.
Krhut J, Havránek O. Léčba hyperaktivního měchýře u žen. Urol List 2009; 7(4): 50–54.
Abrams P, Cardozo L, Wagg A et al (eds). Incontinence. ICI-ICS. 6th International Consultation on Incontinence, Tokyo, September 2016. 6th ed. International Consultation on Incontinence and International Continence Society, Bristol (UK) 2017. ISBN: 978–0956960733.
Horčička L. Inkontinence moči v každodenní praxi, 2. ed. Mladá fronta: Praha 2017. ISBN 978–80–204–4503–2.
Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Phamacokinet 2003; 42(14): 1243–1285. Dostupné z DOI:<http://dx.doi.org/10.2165/00003088–200342140–00004>.
Abrams P, Cardozo L, Khouryet S et al. Incontinence. 5th International Consultation on Incontinence, Paris, 2012. ISBN 9789953493213.
Topinková E. Farmakoterapie hyperaktivního močového měchýře ve stáří. Medicína po promoci 2010; 11: (Suppl 1–2): 36–44.
Burkhard FC, Bosch JL, Cruz F et al. Guidelines from the European Association of Urology (EAU) Working Panel on Urinary Incontinence [Cit. 2018–05–31]. Dostupné z WWW: <https://uroweb.org/guideline/urinary-incontinence/#4>.
Topinková E. Farmakoterapie urgentní inkontinence a hyperaktivního měchýře u seniorů. Urol Praxi 2017; 18(4): 148–153.